Walden Biosciences is developing targeted gene editing therapies to modify renal cell function in patients with chronic kidney disease. This approach aims to improve patient outcomes by reducing reliance on dialysis and kidney transplants.
Funding
$51M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic kidney disease (CKD) often necessitates dialysis or kidney transplantation due to the progressive loss of renal function. Current treatments do not directly address the underlying genetic causes of many kidney disorders, leaving a significant unmet need for targeted therapies.
Solution
Walden Biosciences is developing a pipeline of disease-modifying therapies that directly target the kidney to treat CKD. Their approach focuses on using targeted gene editing to modify renal cell function, aiming to slow or reverse disease progression. By addressing the genetic roots of kidney disease, Walden Biosciences seeks to reduce the reliance on dialysis and kidney transplants, ultimately improving patient outcomes and quality of life. Their pipeline includes novel therapies designed to precisely target and correct specific genetic defects within the kidney.
Target Audience
The primary target audience includes patients with chronic kidney disease and the physicians who treat them, as well as clinical researchers focused on developing new treatments for kidney disorders.
Features
- Targeted gene editing therapies designed to modify renal cell function.
- Focus on disease-modifying treatments that address the underlying causes of CKD.
- Pipeline of novel therapies in development, including WAL0921 and WAL0623.
- Therapies designed to reduce or eliminate the need for dialysis and kidney transplantation.